Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The company's Instruments segment designs, manufactures, and markets quality control hardware and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. This segment's products include dialysate meters and calibration solutions, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company's Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Continuous Monitoring segment designs, develops, and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
IPO Year:
Exchange: NASDAQ
Website: mesalabs.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2024 | $120.00 | Underweight | Wells Fargo |
| 1/4/2024 | $100.00 → $125.00 | In-line → Outperform | Evercore ISI |
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
10-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa", "we", "us", or "our"), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the "Board"), effective January 5, 2024. Dr. John Sullivan, Ph.D., Chairman of the Board of Directors, stated: "We are pleased to welcome Mark to Mesa's Board. Mark is an accomplished life sciences executive with significant leadership and acquisitions experience spanning biopharmaceuticals, life science tools, and clinical genomics. We believe Mark's insights will be pivotal to Mesa
LAKEWOOD, Colo., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or the "Company") today announced that Shiraz Ladiwala has been appointed to serve as the Lead Independent Director of its Board of Directors ("Board"), effective November 3, 2022. Mr. Ladiwala assumes this newly re-created role as an expansion of his current responsibilities on the Board, on which he has served since October 2021. Mr. Ladiwala was selected for this important role due to the thoughtful leadership and contributions he has made to the Board as well as the exceptional breadth of his professional experience. Mr. Ladiwala said, "I am delighted to accept this leadership role on Mes
LAKEWOOD, Colo., June 27, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the "Board"), effective June 23, 2022. Tony was previously the Executive Vice President and Chief Financial Officer of Corning, Incorporated and retired on May 2, 2022. With Mr. Tripeny's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. Mr. Tripeny is likely to be appointed to the Audit Committee and brings extensive financial experience to the Board. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent
LAKEWOOD, Colo., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Shiraz Ladiwala to its Board of Directors, effective October 28, 2021. Shiraz previously worked in leadership roles at Thermo Fisher Scientific and retired on August 31, 2021. With Mr. Ladiwala's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. "Shiraz's extensive experience building a world class life sciences company and his knowledge in corporate development and the Asia/ Pacific region will be instrumental to helping Mesa achieve its strategic objectives" said John Sullivan, Ph.D
LAKEWOOD, Colo., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa Labs” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2021, to shareholders of record at the close of business on February 26, 2021. About Mesa Laboratories, Inc.Mesa Labs is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, medical device, industrial safety, environmental, and food and beverage industries. Mesa Labs offers products and services through four divisions (St
LAKEWOOD, Colo., May 28, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter ("4Q25") and full fiscal year ("FY25") ended March 31, 2025 (amounts in thousands). Fourth quarter FY25 compared to fourth quarter FY24: Revenues increased 5.5%Non-GAAP core organic revenues growth1 was 6.3%Operating income increased 100.5% to $1,469Non-GAAP adjusted operating income ("AOI") excluding unusual items2 decreased 18.0% and was 19.7% as a percentage of revenues Full FY25 compared to full FY24:
LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p
LAKEWOOD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter ("3Q25") ended December 31, 2024 (amounts in thousands). Third quarter FY 2025 compared to third quarter FY 2024: Revenues increased 17.5%Non-GAAP core organic revenues1 increase was 13.2%Operating income increased 8,725% to $5,779Non-GAAP adjusted operating income excluding unusual items2 increased 13.3% and was 23.5% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"
LAKEWOOD, Colo., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2025 at approximately 8:00 A.M. Eastern time on Tuesday, February 4, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. CONTACT: Gary Owens, President and
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa
LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter ("2Q25") ended September 30, 2024 (amounts in thousands). Second quarter FY 2025 compared to second quarter FY 2024: Revenues increased 8.8%Non-GAAP core organic revenues¹ decline was 2.8%Operating income increased 5,947% to $3,508 Non-GAAP adjusted operating income excluding unusual items² increased 18.9% and was 24.8% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"), Cl
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
LAKEWOOD, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter ("1Q25") ended June 30, 2024 (amounts in thousands). First quarter FY 2025 compared to first quarter FY 2024: Revenues increased 14.9%Non-GAAP core organic revenues1 growth was 3.0%Operating income increased 940%Non-GAAP adjusted operating income excluding unusual items2 increased 47.0% and was 26.4% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"), Clinical Genomics ("
Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter ("4Q24") and fiscal year ("FY24") ended March 31, 2024 (amounts in thousands). Fourth quarter FY24 compared to fourth quarter FY23: Revenues increased 6% and increased 10.2% vs 3Q24Non-GAAP core organic revenues1 decreased 3.5%Operating (loss) was $(271,284) which included a $274,533 non-cash impairment chargeNon-GAAP adjusted operating income excluding unusual items2 increased 26.3% and was 25.4% as a percentage of revenues Full
LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p
LAKEWOOD, Colo. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product
Lakewood, Colo., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa", "we", "us" or "our"), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the completed acquisition of GKE-GmbH's sterilization indicators business and its accredited, independent testing lab SAL GmbH. Additionally, Mesa has entered into a definitive agreement to purchase GKE's Chinese sales entity, Beijing GKE Science & Technology Co. LTD ("GKE China"). The total purchase price for the acquisition of the three entities is €85M (of which €5M is associated with GKE China), which is subject to customary purchase price adj
LAKEWOOD, Colo., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, i
LAKEWOOD, Colo., July 05, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integ
LAKEWOOD, Colo., April 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2023, to shareholders of record at the close of business on May 31, 2023. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
Wells Fargo initiated coverage of Mesa Laboratories with a rating of Underweight and set a new price target of $120.00
Evercore ISI upgraded Mesa Laboratories from In-line to Outperform and set a new price target of $125.00 from $100.00 previously
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)